EP Patent

EP1196396B1 — Pharmacologically active compounds with two covalently linked active principles (sodium channnel blocker/p2y2 receptor agonist) for the treatment of mucosal surfaces

Assigned to University of North Carolina at Chapel Hill · Expires 2008-03-26 · 18y expired

What this patent protects

Compounds of the general formula P1-L-P2; wherein "P1" is a pyrazinoylguanidine sodium channel blocker, "L" is a linking group, and "P2" is either (i) a pyrazinoylguanidine sodium channel blocker or (ii) a P2Y2 receptor agonist, are disclosed. Pharmaceutic…

USPTO Abstract

Compounds of the general formula P1-L-P2; wherein "P1" is a pyrazinoylguanidine sodium channel blocker, "L" is a linking group, and "P2" is either (i) a pyrazinoylguanidine sodium channel blocker or (ii) a P2Y2 receptor agonist, are disclosed. Pharmaceutical formulations containing the same and methods of use thereof to hydrate mucosal surfaces such as airway mucosal surfaces are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP1196396B1
Jurisdiction
EP
Classification
—
Expires
2008-03-26
Drug substance claim
No
Drug product claim
No
Assignee
University of North Carolina at Chapel Hill
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.